The Beauty Health Company Sees Q1 Revenue $77M-$83M Vs $85.53M Est.; FY24 Revenue Flat To Low-single Digit % Growth
Portfolio Pulse from Benzinga Newsdesk
The Beauty Health Company (SKIN) projects Q1 revenue to be between $77M-$83M, below the estimated $85.53M, and anticipates flat to low-single digit percentage growth for FY24. The company expects a seasonally low Q1 due to increased sales and marketing investments, with an adjusted EBITDA of ($6)-($9) million for Q1 and over $40 million for FY24, assuming stable market conditions and excluding unforeseen events or transactions.
March 12, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The Beauty Health Company expects lower Q1 revenue than estimated and minimal growth in FY24, with significant investments in marketing.
The projected Q1 revenue miss and modest FY24 growth outlook for SKIN, coupled with increased marketing expenses, could lead to negative investor sentiment in the short term. The company's acknowledgment of seasonal sales fluctuations and external market risks further justifies a cautious approach to its stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100